ROIS Reflects On 2025: Innovation & Investment

The past few years have been transformative for ROIS, marking a defining phase in its evolution into a true pure-play CDMO — and 2025 has been no exception. With a clear strategic focus on complex, high-value sterile injectables, the Spain-based company has pursued an ambitious growth agenda underpinned by significant investment across its operations.

This expansion includes the deployment of state-of-the-art filling technologies, the development of new manufacturing facilities, and the addition of substantial drug product capacity, alongside new device assembly and packaging lines. In parallel, ROIS has accelerated its international footprint through geographic expansion into the United States, anchored by a major strategic acquisition that strengthens its global reach and customer proximity.

Collectively, these initiatives have repositioned ROIS from a regional specialist into a truly global contract development and manufacturing partner. Today, the Madrid-headquartered CDMO ranks among the leading providers worldwide for injectable drug product manufacturing, combining advanced technical capabilities with the scale, quality, and reliability demanded by the industry’s most complex programs.